Lymph Node Metastasis and Recurrences from Esophageal Squamous Cell Carcinoma in Patients with Previous Gastrectomy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
07
03
2020
pubmed:
18
6
2020
medline:
28
4
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
Esophageal cancer patients sometimes have a history of previous gastrectomy. To determine whether we should resect or preserve the remnant stomach, we need to understand the frequency and sites of abdominal lymph node (LN) metastasis from esophageal cancer after gastrectomy. In 46 patients with thoracic esophageal squamous cell carcinoma (ESCC) who had a history of previous gastrectomy due to gastric cancer (n = 20) or benign disease (n = 26), the frequency and sites of any LN metastasis including LN metastasis at surgery and LN recurrence were investigated. The factors associated with abdominal LN metastasis were also examined. The incidence of metastasis to cervical, mediastinal, and abdominal LNs at surgery was 10.8%, 30.4%, and 30.4%, respectively. The incidence of abdominal LN recurrence was 6.5%. Of 46 patients, 16 patients (34.8%) had any abdominal LN metastasis, including abdominal LN metastasis at surgery or abdominal LN recurrence. There was no significant difference in the incidence of any abdominal LN metastasis between the gastric cancer group and the benign disease group (25.0% vs. 42.3%, p = 0.222). Clinically, nodal status was identified as the only independent factor associated with the occurrence of any abdominal LN metastasis, although neither tumor location nor the reason for gastrectomy was. The present study showed that the incidence of abdominal LN metastasis from ESCC after gastrectomy was not necessarily low, regardless of the tumor location and the reason for previous gastrectomy. This result suggests that gastrectomy should not be omitted easily in ESCC patients after previous gastrectomy.
Sections du résumé
BACKGROUND
BACKGROUND
Esophageal cancer patients sometimes have a history of previous gastrectomy. To determine whether we should resect or preserve the remnant stomach, we need to understand the frequency and sites of abdominal lymph node (LN) metastasis from esophageal cancer after gastrectomy.
PATIENTS AND METHODS
METHODS
In 46 patients with thoracic esophageal squamous cell carcinoma (ESCC) who had a history of previous gastrectomy due to gastric cancer (n = 20) or benign disease (n = 26), the frequency and sites of any LN metastasis including LN metastasis at surgery and LN recurrence were investigated. The factors associated with abdominal LN metastasis were also examined.
RESULTS
RESULTS
The incidence of metastasis to cervical, mediastinal, and abdominal LNs at surgery was 10.8%, 30.4%, and 30.4%, respectively. The incidence of abdominal LN recurrence was 6.5%. Of 46 patients, 16 patients (34.8%) had any abdominal LN metastasis, including abdominal LN metastasis at surgery or abdominal LN recurrence. There was no significant difference in the incidence of any abdominal LN metastasis between the gastric cancer group and the benign disease group (25.0% vs. 42.3%, p = 0.222). Clinically, nodal status was identified as the only independent factor associated with the occurrence of any abdominal LN metastasis, although neither tumor location nor the reason for gastrectomy was.
CONCLUSIONS
CONCLUSIONS
The present study showed that the incidence of abdominal LN metastasis from ESCC after gastrectomy was not necessarily low, regardless of the tumor location and the reason for previous gastrectomy. This result suggests that gastrectomy should not be omitted easily in ESCC patients after previous gastrectomy.
Identifiants
pubmed: 32548753
doi: 10.1245/s10434-020-08734-w
pii: 10.1245/s10434-020-08734-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5312-5319Références
Shearman DJ, Arnott SJ, Finlayson ND, Pearson JG. Carcinoma of the oesophagus after gastric surgery. Lancet. 1970;1:581–582.
doi: 10.1016/S0140-6736(70)91623-5
Macdonald JB, Waissbluth JG, Langman MJ. Carcinoma of the oesophagus and gastric surgery. Lancet. 1971;1:19–20.
doi: 10.1016/S0140-6736(71)80008-9
Maeta M, Koga S, Andachi H, Yoshioka H, Wakatsuki T. Esophageal cancer developed after gastrectomy. Surgery. 1986;99:87–91.
pubmed: 3942003
Kato H, Tachimori Y, Watanabe H. Surgical treatment for thoracic esophageal carcinoma in patients after gastrectomy. J Surg Oncol. 1992;51:94–99.
doi: 10.1002/jso.2930510206
Kuwano H, Matsuda H, Nagamatsu M, et al. Occurrence of esophageal carcinoma after gastrectomy. J Surg Oncol. 1989;41:77–80.
doi: 10.1002/jso.2930410205
Tachibana M, Abe S, Yoshimura H, et al. Squamous cell carcinoma of the esophagus after partial gastrectomy. Dysphagia. 1995;10:49–52.
doi: 10.1007/BF00261281
Alexandrou A, Davis PA, Law S, et al. Esophageal cancer in patients with a history of distal gastrectomy. Arch Surg. 2002;137:1238–1242.
doi: 10.1001/archsurg.137.11.1238
Wada H, Doki Y, Nishioka K, et al. Clinical outcome of esophageal cancer patients with history of gastrectomy. J Surg Oncol. 2005;89:67–74.
doi: 10.1002/jso.20194
Nakanishi K, Daiko H, Kato F, et al. Efficacy of preserving the residual stomach in esophageal cancer patients with previous gastrectomy. Gen Thorac Cardiovasc Surg. 2019;67:470–478.
doi: 10.1007/s11748-019-01070-1
Jun W, Wei W, Weibing W, et al. Clinical outcome of using gastric remnant or jejunum or colon conduit in surgery for esophageal carcinoma with previous gastrectomy. J Surg Oncol. 2017;115:729–737.
doi: 10.1002/jso.24564
Poh M, Selber JC, Skoracki R, Walsh GL, Yu P. Technical challenges of total esophageal reconstruction using a supercharged jejunal flap. Ann Surg. 2011;253:1122–1129.
doi: 10.1097/SLA.0b013e318217e875
Iwata N, Koike M, Kamei Y, et al. Antethoracic pedicled jejunum reconstruction with the supercharge technique for esophageal cancer. World J Surg. 2012;36:2622–2629.
doi: 10.1007/s00268-012-1736-4
Blackmon SH, Correa AM, Skoracki R, et al. Supercharged pedicled jejunal interposition for esophageal replacement: a 10-year experience. Ann Thorac Surg. 2012;94:1011–1104.
Shirakawa Y, Naomoto Y, Noma K, et al. Colonic interposition and supercharge for esophageal reconstruction. Langenbecks Arch Surg. 2006;391:19–23.
doi: 10.1007/s00423-005-0010-8
Klink CD, Binnebösel M, Schneider M, et al. Operative outcome of colon interposition in the treatment of esophageal cancer: a 20-year experience. Surgery. 2010;147:491–496.
doi: 10.1016/j.surg.2009.10.045
Hamai Y, Hihara J, Emi M, Aoki Y, Okada M. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery. Surg Today. 2012;42:342–350.
doi: 10.1007/s00595-011-0103-7
Mine S, Udagawa H, Tsutsumi K, et al. Colon interposition after esophagectomy with extended lymphadenectomy for esophageal cancer. Ann Thorac Surg. 2009;88:1647–1653.
doi: 10.1016/j.athoracsur.2009.05.081
Doki Y, Okada K, Miyata H, et al. Long-term and short-term evaluation of esophageal reconstruction using the colon or the jejunum in esophageal cancer patients after gastrectomy. Dis Esophagus. 2008;21:132–138.
doi: 10.1111/j.1442-2050.2007.00738.x
Watanabe M, Mine S, Nishida K, et al. Reconstruction after esophagectomy for esophageal cancer patients with a history of gastrectomy. Gen Thorac Cardiovasc Surg. 2016;64:457–463.
doi: 10.1007/s11748-016-0661-0
Noguchi Y, Imada T, Abe S, et al. Lymphatic flow of the remnant stomach. Nihon Geka Gakkai Zasshi. 1988;89:852–862.
pubmed: 3185472
Miyata H, Sugimura K, Yamasaki M, et al. Clinical impact of the location of lymph node metastases after neoadjuvant chemotherapy for middle and lower thoracic esophageal cancer. Ann Surg Oncol. 2019;26:200–208.
doi: 10.1245/s10434-018-6946-z
Miyata H, Sugimura K, Motoori M, et al. Clinical implications of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26:4737–4743.
doi: 10.1245/s10434-019-07727-8
Tachimori Y, Ozawa S, Numasaki H, et al. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:1–7.
doi: 10.1007/s10388-015-0515-3
Udagawa H, Ueno M, Shinohara H, et al. The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer. J Surg Oncol. 2012;106:742–747.
doi: 10.1002/jso.23122
Miyata H, Yamasaki M, Makino T, et al. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. J Surg Oncol. 2015;112:60–65.
doi: 10.1002/jso.23965
Yamamoto K, Takiguchi S, Miyata H, et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery. 2010;148:31–38.
doi: 10.1016/j.surg.2009.11.026
Takiguchi S, Takata A, Murakami K, et al. Clinical application of ghrelin administration for gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2014;17:200–205.
doi: 10.1007/s10120-013-0300-8
Miyata H, Sugimura K, Motoori M, et al. Clinical features of metastasis from superficial squamous cell carcinoma of the thoracic esophagus. Surgery. 2019;166:1033–1040.
doi: 10.1016/j.surg.2019.07.022
Akutsu Y, Kato K, Igaki H, et al. The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer: from the results of JCOG0502, a prospective multicenter study. Ann Surg. 2016;264:1009–1015.
doi: 10.1097/SLA.0000000000001557
Schlottmann F, Barbetta A, Mungo B, Lidor AO, Molena D. Identification of the lymphatic drainage pattern of esophageal cancer with near-infrared fluorescent imaging. J Laparoendosc Adv Surg Tech A. 2017;27:268–271.
doi: 10.1089/lap.2016.0523
Hachey KJ, Gilmore DM, Armstrong KW, et al. Safety and feasibility of near-infrared image-guided lymphatic mapping of regional lymph nodes in esophageal cancer. J Thorac Cardiovasc Surg. 2016;152:546–554.
doi: 10.1016/j.jtcvs.2016.04.025